Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,039 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of finerenone on the occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR).
Rossing P, Garweg JG, Anker SD, Osonoi T, Pitt B, Rosas SE, Ruilope LM, Zhu D, Brinker M, Finis D, Leal S, Schmelter T, Bakris G. Rossing P, et al. Among authors: bakris g. Diabetes Obes Metab. 2023 Mar;25(3):894-898. doi: 10.1111/dom.14915. Epub 2022 Nov 29. Diabetes Obes Metab. 2023. PMID: 36331803 Free PMC article. No abstract available.
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Bakris GL, et al. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23. N Engl J Med. 2020. PMID: 33264825 Free article. Clinical Trial.
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis.
Mentz RJ, Anker SD, Pitt B, Rossing P, Ruilope LM, Gebel M, Kolkhof P, Lawatscheck R, Rohwedder K, Bakris GL;  on behalf of the FIDELIO‐DKD and FIGARO‐DKD Investigators. Mentz RJ, et al. Among authors: bakris gl. Eur J Heart Fail. 2025 Jan 17. doi: 10.1002/ejhf.3569. Online ahead of print. Eur J Heart Fail. 2025. PMID: 39823276
Design and rationale of the eLym™ System for Decompensation of Excess Lymphatic Fluid via the Thoracic Duct in Acute Heart Failure (DELTA-HF).
Biegus J, Lindenfeld J, Felker GM, Bakris G, Jonas M, Lala A, Kereselidze Z, Khabeishvili G, Gogorishvili I, Núñez J, Bayés-Genís A, Ponikowski P, Abraham WT. Biegus J, et al. Among authors: bakris g. ESC Heart Fail. 2024 Dec 24. doi: 10.1002/ehf2.15192. Online ahead of print. ESC Heart Fail. 2024. PMID: 39716986 Free article.
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials.
Badve SV, Bilal A, Lee MMY, Sattar N, Gerstein HC, Ruff CT, McMurray JJV, Rossing P, Bakris G, Mahaffey KW, Mann JFE, Colhoun HM, Tuttle KR, Pratley RE, Perkovic V. Badve SV, et al. Among authors: bakris g. Lancet Diabetes Endocrinol. 2025 Jan;13(1):15-28. doi: 10.1016/S2213-8587(24)00271-7. Epub 2024 Nov 25. Lancet Diabetes Endocrinol. 2025. PMID: 39608381
Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes.
Filippatos G, Anker SD, Bakris GL, Rossing P, Ruilope LM, Coats AJS, von Haehling S, Ponikowski P, Rosano GMC, Brinker M, Farjat AE, Roberts L, Pitt B; FIDELIO‐DKD and FIGARO‐DKD investigators. Filippatos G, et al. Among authors: bakris gl. ESC Heart Fail. 2024 Sep 3. doi: 10.1002/ehf2.14962. Online ahead of print. ESC Heart Fail. 2024. PMID: 39226189 Free article.
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.
Pratley RE, Tuttle KR, Rossing P, Rasmussen S, Perkovic V, Nielsen OW, Mann JFE, MacIsaac RJ, Kosiborod MN, Kamenov Z, Idorn T, Hansen MB, Hadjadj S, Bakris G, Baeres FMM, Mahaffey KW; FLOW Trial Committees and Investigators. Pratley RE, et al. Among authors: bakris g. J Am Coll Cardiol. 2024 Oct 22;84(17):1615-1628. doi: 10.1016/j.jacc.2024.08.004. Epub 2024 Aug 30. J Am Coll Cardiol. 2024. PMID: 39217553 Free article. Clinical Trial.
Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.
Mahaffey KW, Tuttle KR, Arici M, Baeres FMM, Bakris G, Charytan DM, Cherney DZI, Chernin G, Correa-Rotter R, Gumprecht J, Idorn T, Pugliese G, Rasmussen IKB, Rasmussen S, Rossing P, Sokareva E, Mann JFE, Perkovic V, Pratley R. Mahaffey KW, et al. Among authors: bakris g. Eur Heart J. 2024 Aug 30:ehae613. doi: 10.1093/eurheartj/ehae613. Online ahead of print. Eur Heart J. 2024. PMID: 39211948
1,039 results